source
- Jury awards Nektar $90 million in damages after lawsuit over broken rezpeg partnership with Eli LillyA jury in a US court has ordered Eli Lilly to pay Nektar Therapeutics $90 million after finding the pharma giant breached their collaboration on the experimental autoimmune drug rezpeg. Nektar and…
- Kali Therapeutics pivots from Chinese drug acquisitions to focus on its own growing pipelineKali Therapeutics, the winner of the Endpoints 11 2026 competition, initially explored the possibility of purchasing drug candidates from China. The company ultimately chose to rely on its own res…